Research AI-discovered drug rentosertib enters Phase III trial Rentosertib, an AI-discovered TNIK inhibitor for IPF, enters Phase III with 320 patients. It is the first fully AI-originated drug to reach late-stage trials. Lars Cornelissen · Jul 8, 2026